A NK
1
antagonist having the formula (I),
wherein Ar
1
and Ar
2
are optionally substituted phenyl or heteroaryl, X
1
is an ether, thio or imino linkage, R
4
and R
5
are not both H or alkyl, and the remaining variables are as defined in the specification, useful for treating a number of disorders, including emesis, depression, anxiety and cough. Pharmaceutical compositions. Methods of treatment and combinations with other agents are also disclosed.
PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 8-({1-(3,5-BIS-(TRIFLUOROMETHYL)PHENYL)-ETHOXY}- METHYL -8-PHENYL-1,7-DIAZA-SPIRO[4.5]DECAN-2-ONE COMPOUNDS
申请人:OPKO Health, Inc.
公开号:EP3138836A1
公开(公告)日:2017-03-08
This application discloses a novel process to synthesize 8-[1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds, which may be used, for example, as NK-1 inhibitor compounds in pharmaceutical preparations.